Abstract 901P
Background
Chemoradiation (CRT) in patients (pts) with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including oral mucositis (OM). The gut microbiome (GM) is an emerging biomarker of treatment outcomes and adverse events. This study aimed to investigate the role of GM composition to predict CRT toxicities in HNSCC pts, including development of severe OM.
Methods
We prospectively collected fecal samples of 52 pts with HNSCC undergoing CRT. Using shotgun metagenomic sequencing and MetaPhlAn4 pipeline, LefSe differences in GM composition at baseline were assessed according to CTCAE v4.0 toxicity grading including OM and enteral feeding tube requirement. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.
Results
Most tumors (n=40) were p16-positive, including oropharyngeal (n=35) and unknown primaries (n=4). TNM staging was III-IV in 54% (n=28). After a median follow-up of 27 mo, the 12-mo OS and PFS were 96% and 84%, respectively. In terms of toxicity, OM was seen in all pts, and 22 pts (42%) developed grade ≥3 OM. Thirteen pts (25%) required enteral feeding. Grade ≥3 OM was associated with a significant decrease in OS (p=0.02) even when accounting for staging and p16 status in multivariate analysis (MVA; p<0.05), as well as a numerically shorter PFS (p=0.09). No baseline characteristic correlated with increased risk of severe OM in MVA. However, GM beta-diversity differed between grade 1-2 and grade 3 OM (PERMANOVA p=0.04) but there was no difference in alpha-diversity. Pts with severe OM had distinct GM enriched with Mediterraneibacter (Ruminococcus gnavus) and members of the Clostridiaceae family, including Hungatella hathewayi. In pts with mild OM, Eubacterium rectale, Alistipes putredinis and members of the Ruminococcaceae family were overrepresented. We observed similar microbiome differences in pts requiring enteral feeding.
Conclusions
Severe OM was associated with decreased OS and PFS in pts with HNSCC undergoing CRT. Pts who developed severe OM or required enteral feeding had a distinct GM enriched with deleterious bacteria that have been associated with resistance to immune checkpoint inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Oncobiome grant #825410.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12